Hillstream BioPharma Inc (HILS) USD0.0001
Hillstream BioPharma, Inc. (HBI) is a pre-clinical biotechnology company. The Company is engaged in developing therapeutic candidates targeting ferroptosis, an anti-cancer mechanism resulting in iron mediated cell death (IMCD) for treatment of resistant cancers. Its lead product candidate is HSB-1216, an IMCD modulator, targeting a variety of solid tumors. The drug, HSB-1216 was found to reduce tumor burden treatment resistant cancers, including triple negative breast cancer and epithelial carcinomas. The Company uses Quatramer, a tumor targeting platform to treat rare and treatment resistant cancers. Its Trident Artificial Intelligence, an artificial intelligence precision medicine platform, is used to identify biomarkers in clinical programs to target specific patient segments. HBI's second second product candidate, HSB-888, is a dual-loaded Iron Medicated Cell Death modulator for solid tumors. Its other product candidates are HSB-510 and HSB-114.
The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.
Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.